Evotec To Get Research Grant To Advance H3 Receptor Antagonist Programme
The histamine H3 receptor is a drug target of high interest because of evidence that blocking this receptor in the brain can improve cognition, alertness and attention. H3
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The collaborative program is expected to encompass training for Johns Hopkins researchers in the NYSCF laboratory in Manhattan, specific research collaborations and a NYSCF fellowship to support Johns